UroGen Pharma Ltd.
DE ˙ DB ˙ IL0011407140
23,18 € ↑0,82 (3,67%)
2026-06-05
CENA AKCJI
SecurityDE:UR8 / UroGen Pharma Ltd.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership275,938 shares
Latest Disclosed Value $ 4,961,365
Northern Trust Corp reports 16.21% increase in ownership of UR8 / UroGen Pharma Ltd.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 275,938 shares of UroGen Pharma Ltd. (DE:UR8) valued at $4,028,695 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 237,457 shares of UroGen Pharma Ltd.. This represents a change in shares of 16.21% during the quarter. The current value of the position is $6,396,243 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F UROGEN PHARMA COM M96088105 275,938 38,481 16.21 4,961 -10.79 0.0007
2026-02-17 2025-12-31 13F UROGEN PHARMA COM M96088105 237,457 -23,944 -9.16 5,561 6.66 0.0007
2025-11-14 2025-09-30 13F UROGEN PHARMA COM M96088105 261,401 -6,317 -2.36 5,215 42.19 0.0007
2025-08-13 2025-06-30 13F UROGEN PHARMA COM M96088105 267,718 -17,896 -6.27 3,668 16.12 0.0005
2025-05-13 2025-03-31 13F UROGEN PHARMA COM M96088105 285,614 -24,460 -7.89 3,159 -4.36 0.0005
2025-02-14 2024-12-31 13F UROGEN PHARMA COM M96088105 310,074 23,345 8.14 3,302 -9.31 0.0005
2024-11-13 2024-09-30 13F UROGEN PHARMA COM M96088105 286,729 69,367 31.91 3,641 -0.16 0.0006
2024-08-14 2024-06-30 13F UROGEN PHARMA COM M96088105 217,362 -15,138 -6.51 3,647 4.59 0.0006
2024-05-14 2024-03-31 13F UROGEN PHARMA COM M96088105 232,500 -2,736 -1.16 3,488 -1.16 0.0006
2024-02-13 2023-12-31 13F UROGEN PHARMA COM M96088105 235,236 57,845 32.61 3,529 41.97 0.0006
2023-11-13 2023-09-30 13F UROGEN PHARMA COM M96088105 177,391 -1,792 -1.00 2,485 34.03 0.0005
2023-08-11 2023-06-30 13F UROGEN PHARMA COM M96088105 179,183 157,725 735.04 1,855 836.36 0.0004
2023-05-15 2023-03-31 13F UROGEN PHARMA COM M96088105 21,458 -363 -1.66 198 2.59 0.0000
2023-02-13 2022-12-31 13F UROGEN PHARMA COM M96088105 21,821 -177 -0.80 194 5.46 0.0000
2022-11-14 2022-09-30 13F UROGEN PHARMA COM M96088105 21,998 1,008 4.80 183 6.40 0.0000
2022-08-12 2022-06-30 13F UROGEN PHARMA COM M96088105 20,990 -139,890 -86.95 172 -87.72 0.0000
2022-05-13 2022-03-31 13F UROGEN PHARMA COM M96088105 160,880 -8,421 -4.97 1,401 -13.04 0.0002
2022-02-08 2021-12-31 13F UROGEN PHARMA COM M96088105 169,301 1,277 0.76 1,611 -42.99 0.0003
2021-11-15 2021-09-30 13F UROGEN PHARMA COM M96088105 168,024 -29,530 -14.95 2,826 -6.36 0.0005
2021-08-13 2021-06-30 13F UROGEN PHARMA COM M96088105 197,554 -9,742 -4.70 3,018 -25.28 0.0005
2021-05-12 2021-03-31 13F UROGEN PHARMA COM M96088105 207,296 -32,084 -13.40 4,039 -6.37 0.0008
2021-02-11 2020-12-31 13F UROGEN PHARMA COM M96088105 239,380 -6,583 -2.68 4,314 -9.08 0.0008
2020-11-16 2020-09-30 13F UROGEN PHARMA COM M96088105 245,963 48,244 24.40 4,745 -8.13 0.0010
2020-08-14 2020-06-30 13F UROGEN PHARMA COM M96088105 197,719 -32,308 -14.05 5,165 25.85 0.0012
2020-05-14 2020-03-31 13F UROGEN PHARMA COM M96088105 230,027 2,264 0.99 4,104 -46.00 0.0012
2020-02-14 2019-12-31 13F UROGEN PHARMA COM M96088105 227,763 4,056 1.81 7,600 42.56 0.0017
2019-11-13 2019-09-30 13F UROGEN PHARMA COM M96088105 223,707 168,371 304.27 5,331 168.16 0.0013
2019-08-13 2019-06-30 13F UROGEN PHARMA COM M96088105 55,336 29,142 111.25 1,988 105.37 0.0005
2019-05-13 2019-03-31 13F UROGEN PHARMA COM M96088105 26,194 8,596 48.85 968 27.70 0.0002
2019-02-12 2018-12-31 13F UROGEN PHARMA COM M96088105 17,598 1,600 10.00 758 0.26 0.0002
2018-11-14 2018-09-30 13F UROGEN PHARMA COM M96088105 15,998 2,400 17.65 756 11.67 0.0002
2018-09-18 2018-06-30 13F/A-1 UROGEN PHARMA COM M96088105 13,598 13,598 677 0.0002
2018-08-14 2018-06-30 13F UROGEN PHARMA COM M96088105 13,598 677 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.